Cell- and Tissue-Based Therapy
"Cell- and Tissue-Based Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.
Descriptor ID |
D064987
|
MeSH Number(s) |
E02.095.147
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cell- and Tissue-Based Therapy".
Below are MeSH descriptors whose meaning is more specific than "Cell- and Tissue-Based Therapy".
This graph shows the total number of publications written about "Cell- and Tissue-Based Therapy" by people in this website by year, and whether "Cell- and Tissue-Based Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 0 | 2 | 2 | 2010 | 1 | 0 | 1 | 2011 | 1 | 1 | 2 | 2013 | 0 | 2 | 2 | 2014 | 2 | 1 | 3 | 2015 | 0 | 1 | 1 | 2016 | 3 | 1 | 4 | 2017 | 1 | 1 | 2 | 2018 | 1 | 2 | 3 | 2019 | 0 | 2 | 2 | 2020 | 2 | 3 | 5 | 2021 | 5 | 2 | 7 | 2022 | 0 | 5 | 5 | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Cell- and Tissue-Based Therapy" by people in Profiles.
-
Major A, Kamdar M. Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas. Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):370-381.
-
Kent A, Crump LS, Davila E. Beyond a? T cells: NK, iNKT, and ?dT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML. Front Immunol. 2023; 14:1202950.
-
Rohaan MW, Borch TH, van den Berg JH, Met ?, Kessels R, Geukes Foppen MH, Stoltenborg Granh?j J, Nuijen B, Nijenhuis C, Jedema I, van Zon M, Scheij S, Beijnen JH, Hansen M, Voermans C, Noringriis IM, Monberg TJ, Holmstroem RB, Wever LDV, van Dijk M, Grijpink-Ongering LG, Valkenet LHM, Torres Acosta A, Karger M, Borgers JSW, Ten Ham RMT, Ret?l VP, van Harten WH, Lalezari F, van Tinteren H, van der Veldt AAM, Hospers GAP, Stevense-den Boer MAM, Suijkerbuijk KPM, Aarts MJB, Piersma D, van den Eertwegh AJM, de Groot JB, Vreugdenhil G, Kapiteijn E, Boers-Sonderen MJ, Fiets WE, van den Berkmortel FWPJ, Ellebaek E, H?lmich LR, van Akkooi ACJ, van Houdt WJ, Wouters MWJM, van Thienen JV, Blank CU, Meerveld-Eggink A, Klobuch S, Wilgenhof S, Schumacher TN, Donia M, Svane IM, Haanen JBAG. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022 12 08; 387(23):2113-2125.
-
Logan GE, Miller K, Kohler ME, Loi M, Maddux AB. Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study. Pediatr Crit Care Med. 2022 12 01; 23(12):e595-e600.
-
Dioverti V, Boghdadly ZE, Shahid Z, Waghmare A, Abidi MZ, Pergam S, Boeckh M, Dadwal S, Kamboj M, Seo S, Chemaly RF, Papanicolaou GA. Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). Transplant Cell Ther. 2022 12; 28(12):810-821.
-
Steiner RE, Banchs J, Koutroumpakis E, Becnel M, Gutierrez C, Strati P, Pinnix CC, Feng L, Rondon G, Claussen C, Palaskas N, Karimzad K, Ahmed S, Neelapu SS, Shpall E, Wang M, Vega F, Westin J, Nastoupil LJ, Deswal A. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica. 2022 07 01; 107(7):1555-1566.
-
Mullinax JE, Egger ME, McCarter M, Monk BJ, Toloza EM, Brousseau S, Jagasia M, Sarnaik A. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Cancer J. 2022 Jul-Aug 01; 28(4):285-293.
-
Martits-Chalangari K, Spak CW, Askar M, Killian A, Fisher TL, Atillasoy E, Marshall WL, McNeel D, Miller MD, Mathai SK, Gottlieb RL. ALVR109, an off-the-shelf partially HLA matched SARS-CoV-2-specific T cell therapy, to treat refractory severe COVID-19 pneumonia in a heart transplant patient: Case report. Am J Transplant. 2022 04; 22(4):1261-1265.
-
Borgers JSW, Heimovaara JH, Cardonick E, Dierickx D, Lambertini M, Haanen JBAG, Amant F. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 2021 12; 22(12):e550-e561.
-
Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 12; 56(12):2911-2921.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|